Use of Novel Agent PuraStat® for Post-Ampullectomy Bleeding

Authors

Bertilia Tavarez, MD, MS, Thomas Jefferson University HospitalFollow
Ananya Venkatesh, MD, Thomas Jefferson University HospitalFollow
Pedra Palacios Argueta, MD, Thomas Jefferson University HospitalFollow
Anand Kumar, MD, Thomas Jefferson University HospitalFollow
Alana Persaud, MD, Thomas Jefferson University Hospital
Yasi Xiao, MD, Thomas Jefferson University HospitalFollow
Alexander Schlachterman, MD, Thomas Jefferson University HospitalFollow
Faisal Kamal, MD, Thomas Jefferson University HospitalFollow
Thomas Kowalski, MD, Thomas Jefferson University HospitalFollow

Abstract

Endoscopic ampullectomy is the first line treatment modality for major papilla neoplasms that have not invaded the muscularis propria.¹ Complications of endoscopic ampullectomy include bleeding, pancreatitis, perforation, papillary stenosis, and cholangitis with the incidence of post-ampullectomy bleeding reported to be as high as 30%.^1,2 PuraStat® is a new synthetic hemostatic gel being used for the prophylaxis and treatment of gastrointestinal bleeding.^3-5 To date, there are no reports on the use of PuraStat® for post-ampullectomy bleeding. We hope to investigate the use and outcomes of PuraStat® for post-ampullectomy bleeding.

Recommended Citation

Tavarez, MD, MS, Bertilia; Venkatesh, MD, Ananya; Palacios Argueta, MD, Pedra; Kumar, MD, Anand; Persaud, MD, Alana; Xiao, MD, Yasi; Schlachterman, MD, Alexander; Kamal, MD, Faisal; and Kowalski, MD, Thomas (2025) "Use of Novel Agent PuraStat® for Post-Ampullectomy Bleeding," The Medicine Forum: Vol. 26, Article 18.
Available at: https://jdc.jefferson.edu/tmf/vol26/iss1/18